China has lifted its HPAI-related import bans on U.S. poultry from 17 states, boosting trade prospects and highlighting biosecurity advancements.

In a major development for the U.S. poultry industry, China has lifted its highly pathogenic avian influenza (HPAI) import bans on poultry from 17 U.S. states, effective May 15, 2026. This decision follows bilateral negotiations and reflects a commitment to regionalization protocols. The policy change restores export access to states like Alabama, Nebraska, and Texas, which have been restricted due to wild bird-mediated HPAI detections. This opening is expected to revitalize the poultry export market, which has been constrained by international trade bans since 2022.

Simultaneously, the Swine Health Information Center (SHIC) released its May 2026 report, indicating a concerning rise in wean-to-market PRRS case positivity, reaching a 10-year high of 46%. The report highlights the prevalence of 1C.5 and 1C.2 variants, urging swine producers to reinforce biosecurity measures. The resurgence of PRRS cases, particularly in the Midwest, poses a significant challenge to the swine industry, necessitating immediate attention to disease management and prevention strategies.

The lifting of HPAI bans by China is a major win for U.S. poultry producers, potentially increasing export volumes and trade revenues. For states like Alabama and Texas, which rely heavily on trade, this development could restore valuable market access and boost rural economies. However, the concurrent rise in PRRS cases in the swine industry underscores the urgent need for continued vigilance. The high positivity rate of PRRS threatens to inflate production costs and disrupt pork supply chains, presenting a severe economic challenge for swine producers in key swine regions.

The dual focus on resolving HPAI trade barriers and managing PRRS outbreaks highlights the ongoing challenges and opportunities within the U.S. animal agriculture sector. While poultry producers are poised to benefit from renewed access to Chinese markets, swine producers must navigate the complexities of disease control in a high-risk environment. This situation emphasizes the critical role of biosecurity protocols and the need for industry-wide collaboration to safeguard animal health and trade stability.

Stakeholders should closely monitor the impact of China's decision on U.S. poultry export volumes and market prices, as increased demand from China could lead to shifts in domestic supply dynamics. Additionally, the industry must remain alert to any further developments in PRRS management, such as new vaccine approvals or regulatory changes aimed at controlling the disease. The upcoming USDA APHIS updates on disease monitoring and biosecurity recommendations will be crucial for producers seeking to mitigate the impact of PRRS on their operations.

Looking ahead, industry professionals should prepare for potential policy adjustments and trade negotiations that could arise from this new export landscape. The focus on enhancing biosecurity measures will likely remain a priority, with implications for resource allocation and strategic planning across both the poultry and swine sectors. Staying informed about these developments will be essential for maintaining competitive advantage and ensuring sustainable growth in the U.S. animal agriculture industry.

The lifting of China's HPAI restrictions on U.S. poultry provides a vital boost to exports, yet the simultaneous surge in PRRS case positivity serves as a stark reminder of animal health volatility. U.S. animal agriculture must prioritize strict biosecurity to secure newly reopened international markets while mitigating domestic disease threats. Moving forward, maintaining production efficiency and trade resilience will depend entirely on coordinated disease monitoring and farm-level execution.